Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.37 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622439 | 0.84 | BRD4 (0.37) | PDPK1PYCR1AKR1B1DGAT1 | |
| SCHEMBL2145125 | 0.81 | PDPK1 (0.48) | PDPK1PYCR1AKR1B1DGAT1CHRM5 | |
| SCHEMBL1897113 | 0.80 | ERN1 (0.47) | — | |
| SCHEMBL5451047 | 0.80 | LMNA (0.43) | PDPK1PYCR1AKR1B1DGAT1CHRM5 | |
| SCHEMBL1122006 | 0.79 | IDO1 (0.48) | — | |
| SCHEMBL29953348 | 0.79 | IDO1 (0.48) | — | |
| SCHEMBL5738944 | 0.79 | HSP90AA1 (0.41) | PYCR1HSP90AA1 | |
| SCHEMBL6739825 | 0.78 | KDM4E (0.38) | HSP90AA1 | |
| SCHEMBL2095254 | 0.77 | PYCR1 (0.46) | PDPK1PYCR1AKR1B1DGAT1CHRM5 | |
| SCHEMBL2094594 | 0.77 | PYCR1 (0.46) | PDPK1PYCR1AKR1B1DGAT1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101751-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACERS FOR THE COMPLEMENT C3A RECEPTOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4737437-A1 | DPP1 INHIBITOR INTERMEDIATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINES | Haisco Pharmaceuticals Pte. Ltd. (SG) | 2026-05-06 | — | — | EP | disclosed |
| EP-4547662-A1 | IMIDAZO[4,5-B]PYRIDINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | F. Hoffmann-La Roche AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025002093-A1 | DPP1 INHIBITOR INTERMEDIATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINES | 西藏海思科制药有限公司 | 2025-01-02 | — | — | WO | disclosed |
| WO-2024003208-A1 | IMIDAZO[4,5-B]PYRIDINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-3168219-B1 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYL METHYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| EP-3426244-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3285581-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-2049118-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2035413-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| EP-1989188-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008011551-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008000421-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007100852-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |